The first phase I clinical trial with TCR-modified CTLs was performed as a melanoma therapy in 2006[71], and WT1- and BCR-ABL-specific TCR-modified CTLs have potential for CML immunotherapy in future. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.